The use of absolute values improves performance of estimation formulae: a retrospective cross sectional study by unknown
Redal-Baigorri et al. BMC Nephrology 2013, 14:271
http://www.biomedcentral.com/1471-2369/14/271RESEARCH ARTICLE Open AccessThe use of absolute values improves performance
of estimation formulae: a retrospective cross
sectional study
Belén Redal-Baigorri1*, Knud Rasmussen1 and James Goya Heaf2Abstract
Background: Estimation of Glomerular Filtration Rate (GFR) by equations such as Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) or Modification of Diet in Renal Disease (MDRD) is usually expressed as a
Body Surface Area (BSA) indexed value (ml/min per 1.73 m2). This can have severe clinical consequences in patients
with extreme body sizes, resulting in an underestimation in the case of obesity or an overestimation of GFR in the
case of underweight patients. The aim of this study was to compare the performance of both estimation formula
expressed in ml/min, instead of ml/min per 1.73 m2, with a reference method.
Methods: Retrospective single centre cross sectional study of 185 patients. GFR was measured with 51Cr-EDTA and
estimated with CKD-EPI and MDRD. Bias, precision and accuracy of absolute estimated GFR was calculated.
Results: Bias of CKD-EPI and MDRD formulae expressed as an absolute value was 0.49 and 0.27 ml/min respectively,
which is lower than previously reported. Precision was 12.95 and 16.33 and accuracy expressed as P30 was over
92.43% for CKD-EPI. There were no significant differences in GFR between the reference method and the estimation
formulae.
Conclusions: The performance of CKD-EPI and MDRD formulae can be significantly improved in the individual
patient if the absolute values are used by removing the BSA normalization factor. Absolute estimated GFR by CKD-EPI
is comparable to measured GFR, improving the performance of this formula in the assessment of individual kidney
function, thus providing clinicians with an alternative to reference methods.Background
Glomerular filtration rate (GFR) is accepted as the best
indicator of kidney function in clinical practice, and its
measurement using urinary or plasma clearance of
exogenous filtration markers is considered the gold
standard [1]. In clinical practice, measuring GFR by these
methods is impractical, expensive and in some cases
unnecessary. This is one of the reasons why estimating
equations have emerged.
Estimated GFR (e-GFR) is nearly always expressed as
a Body Surface Area (BSA) indexed value (ml/min per
1.73 m2).
Measured GFR (m-GFR) can be expressed as an absolute
value (ml/min) or a BSA indexed value (ml/min per* Correspondence: belenredal@hotmail.com
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distribution, and reproduction in any medium1.73 m2). These results are comparable as long as the
patient has a BSA around 1.73 m2, which is the reference
value in use over the last century. Whether this value of
1.73 m2 reflects a normal BSA nowadays, is disputable [2].
It is important for clinicians to be aware of the impli-
cations of using BSA indexed GFR values in populations
with extreme BSA values, as suggested by an increasing
amount of scientific papers investigating relationship
between GFR and BSA over the last ten years [3-5].
Several studies have demonstrated that normalization
of GFR with BSA in those cases with extreme body sizes
might be misleading [6] and other studies have documented
that obese patients have higher absolute GFR values
than lean patients, independent of diabetes and hyper-
tension [7-10].
There are different reasons why we keep using BSA
as a normalization index of GFR, as already elegantlyentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Redal-Baigorri et al. BMC Nephrology 2013, 14:271 Page 2 of 8
http://www.biomedcentral.com/1471-2369/14/271discussed by Delanaye [11], but the most important of
them is to allow comparisons of different populations.
The impact of indexing GFR by BSA can be rather
important if the results are to be used for drug dosing
[12] or evaluation of kidney living donor in those patients
outside the normal range of BSA [13]. In both cases,
knowing the real individual kidney function is rather
important. This is already recommended by the National
Kidney Education Program (NKDEP) that suggests using
the absolute GFR values in individual drug dosing of
patients with extreme body sizes, as well as to consider
measuring renal function with exogenous filtration
markers when prescribing drugs with narrow thera-
peutic indices [14].
In practice very few are aware of these recommen-
dations and most professionals use the BSA indexed
GFR values.
For these reasons we decided to investigate whether
the use of estimated absolute GFR values obtained with
Modification of diet in renal disease (MDRD) and chronic
kidney disease epidemiology collaboration (CKD-EPI)
formula is comparable to absolute GFR values obtained
with a gold standard method, thus avoiding professionals
the need of investigating patients with expensive isotope
methods, without compromising the quality of the results.
Methods
Retrospective single centre cross-sectional study of
patients who had their kidney function measured with
a reference method, 51 chromium ethylene diamine
tetraacetic acid clearance (51Cr-EDTA).
An analysis of differences between absolute GFR values
obtained with 51Cr-EDTA and two creatinine-based esti-
mation formulae: CKD-EPI and MDRD was performed.
The study was approved by the Danish Data Protection
Agency (j.nr 2007-41-1006) and conducted in agreement
with the principles of the Declaration of Helsinki.
Participants
A total of 362 patients were referred to the local Depart-
ment of Nuclear and Clinical Physiology in order to de-
termine GFR by 51Cr-EDTA over a 2 year period. All
patients were examined at the same laboratory.
The inclusion criteria were: Age ≥ 18; a minimum of
two serum creatinine values with less than 15% variation
in range within a period of three months and a serum
creatinine value measured a maximum of three weeks
before the 51Cr-EDTA measurement. We only used the
first value of 51Cr-EDTA in those cases where this test
was performed more than once.
Exclusion criteria: Only one creatinine value determin-
ation; acute renal insufficiency; diabetic ketoacidosis;
increased values of protein (plasma (P) protein > 90 g/l),
glucose (P glucose > 17 mmol/l), bilirubin (P bilirubin >65 micromole/l) or uric acid (P uric acid > 0.45 mmol/l);
renal replacement therapy; pregnancy; amputation;
treatment with cephalosporin, cimetidine, methyldopa
or trimethoprim.
The study population had not been diagnosed with
end-stage renal disease (ESRD), as renal replacement
therapy was an exclusion criterion. None of the patients
were undergoing treatment with erythropoietin (EPO) or
active D vitamin at the time of inclusion.
A total of 189 consecutive patients fulfilled the inclusion
criteria.
Four were excluded due to a high serum level of uric acid
[15], leaving 185 patients included for further analysis.
This patient population is now included in a larger
meta-analysis [16].
Estimated glomerular filtration rate
Analysis of serum creatinine
Serum creatinine was measured with the Jaffé method
(Abbott Architect C systems TMc8000, reagent 7D64)
which was calibrated with Isotope Dilution Mass Spec-
trometry (IDMS).
Calculation of estimated glomerular filtration rate
The MDRD and CKD-EPI formulas have previously been
validated in patients with CKD stage 3 or lower, defined as
GFR ≤ 59 ml/min per 1.73 m2. Validation was set at this
level because higher values are associated with increased
imprecision.
CKD-EPI equation: e ‐ GFR = 141 × min (Scr/k, 1)ª ×
max (Scr/k, 1)‐ 1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black].
Where Scr is serum creatinine, k is 0.7 for females and
0.9 for males, a is −0.329 for females and −0.411 for
males, min indicates the minimum of Scr/k or 1, and
max indicates the maximum of Scr/k or 1.
Modification of diet in renal disease formula (14)
based on serum creatinine (Sc), age, gender and race
e‐GFR

ml=minper1:73m2 ¼ 175  Scr=88:4ð Þ‐1:154  age‐0:203
 0:742 if femaleð Þ  1:21 if blackð ÞÞ:
Where Scr is in micromoles/l; 88.4 is the molecular
weight of Scr and age is stated in years.
Body surface area (BSA) was calculated from the DuBois
& DuBois formula with height in centimeters rather
than meters, as BSA(m2) = 0.007184 × height (cm)0.725 ×
weight (kg)0.425.
We looked at absolute values and indexed values;
therefore we used these formulae to convert one to
another.
Table 1 Patient characteristics
Patients (n) 185
Mean age ± SD, years 63 ± 10
Female, n (%) 104 (56)
Male, n (%) 81 (44)
Mean creatinine, mmol/L ± SD 73 ± 21
Mean m-GFR ± SD ml/min 88 ± 25
Mean e-GFR by CKD-EPI ± SD ml/min 89 ± 21
Mean e-GFR by MDRD ± SD ml/min 88 ± 25
Mean BMI, kg/m2 24.2
Mean BSA ± SD, m2 1.78 ± 0.20
SD: Standard deviation; m-GFR: Measured glomerular filtration rate; e-GFR:
Estimated glomerular filtration rate; CKD-EPI: Chronic kidney disease
epidemiology collaboration formula; MDRD: Modification of diet in renal
disease formula. BMI: Body mass index; BSA: Body surface area.
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GFR values
AbsoluteGFR ¼ BSAindexedestimatedGFR PatientsBSAð Þ
=1:73m2 ¼ ml=min:
Conversion of absolute GFR values to BSA indexed
GFR values
BSAIndexedGFR ¼ absoluteGFR 1:73m2 =PatientsBSA
¼ ml=minper1:73m2:
Measured Glomerular Filtration Rate (m-GFR)
GFR was determined from the total (renal and extra-
renal) 51Cr-EDTA plasma clearance by a simplified single-
injection technique with a single-plasma sample [17].
Statistics
Data was analyzed with Excel and Statistica 99 version,
by StatSoft inc. All GFR measurements and estimates
follow a normal distribution.Table 2 Bias, precision and accuracy results of e-GFR with CK
n B
Whole group MDRD ml/min 185 0.27 (−2.
CKD-EPI ml/min 185 0.49 (−1.
BSA < 1.60 m2 MDRD ml/min 34 3.18 (−1.
CKD-EPI ml/min 34 3.66 (−0.
BSA < 1.80 m2 MDRD ml/min 81 −1.64 (−4
CKD-EPI ml/min 81 −0.68 (−3
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration formula; MDRD: Modif
interquartile range; P10 and P30: accuracy within 10 and 30% limits of the measureBias, precision and accuracy of e-GFR
Bias in this study is an expression of systemic error of
estimated absolute GFR and was defined as the mean
difference between estimated and measured absolute GFR.
Precision is an expression of the random variation or
spread of estimated GFR around the measured GFR. It
was expressed as the standard deviation (SD) of the bias.
Large width equals low precision. Both precision and bias
were expressed as ml/min.
Accuracy is affected by both bias and imprecision and
was defined as the percentage of estimated GFR values
within 10% and 30% limits of the measured GFR. Values
over 90% are considered as indicators of high accuracy.Comparison of absolute m-GFR versus absolute e-GFR
We investigated whether there were differences between
measured and estimated GFR whenever results were
expressed independently from BSA, in other words, GFR
was expressed as an absolute value (ml/min) rather than
as a BSA indexed value (ml/min per 1.73 m2).
Our hypothesis was that there were no differences in
between the absolute m-GFR by 51Cr-EDTA or absolute
e-GFR by CKD-EPI or MDRD.A T test for unpaired data
was used, values of P <0.05 were considered significant.
We also performed an analysis where the BSA indexed
values where compared against the absolute values for
all the three methods to ascertain whether the bias
found with 51Cr-EDTA, was also confirmed with CKD-
EPI and MDRD formulae. We also analyzed data with a
Bland Altman plot as this is the recommended analysis
to compare methods.Results
In this study we looked at the performance of these two
formulae whenever the results are expressed in absolute
values, to avoid a possible influence of BSA in the results.
In a previous similar study based on the same set of
data we looked at similar results but only using the
BSA indexed values [17].D-EPI and MDRD
ias Precision IQR P10 P30
09 to 2.64) 16.33 20.27 52.43% 88.11%
38 to 2.37) 12.95 17.28 52.43% 92.43%
76 to 8.14) 14.20 17.67 47.06% 82.35%
82 to 8.14) 12.85 18.81 47.06% 79.41%
.58 to 1.30) 13.29 17.32 56.79% 97.53%
.30 to 1.94) 11.85 14.67 56.79% 98.77%
ication of diet in renal disease formula; BSA: Body surface area. IQR:
d glomerular filtration rate; BSA: body surface area.
Table 3 Comparison of CKD-EPI and MDRD versus 51Cr-EDTA as absolute GFR values (ml/min)
All participants Women Men
N Mean bias (95% C.I) Std dev. P value N Mean bias (95% C.I) Std dev. P value N Mean bias (95% C.I) Std dev. P value
CKD-EPI versus
51-CR-EDTA ml/min
all 185 0.49 (−1.38 to 2.37) 12.95 0.83 104 0.86 (−1.70 to 3.44) 13.23 0.73 81 0.01 (−2.78 to 2.81) 12.65 0.99
BSA < 1.60 34 3.66 (−0.82 to 8.14) 12.85 0.35 32 2.65 (−1.87 to 7.18) 12.56 0.52 2 19.76 (−0.03 to 39.57) 2.2 <0.05
BSA 1.60-1.79 70 0.31 (−3.05 to 3.67) 14.11 0.91 52 −0.70 (−4.69 to 3.27) 14.31 0.81 18 3.25 (−3.42 to 9.94) 13.44 0.66
BSA > 1.80 81 −0.68 (−3.30 to 1.94) 11.85 0.86 20 2.10 (−3.18 to 7.40) 11.31 0.74 61 −1.59 (−4.65 to 1.47) 11.97 0.73
MDRD versus
51CR-EDTA ml/min
all 185 0.27 (−2.09 to 2.64) 16.33 0.91 104 −1.66 (−4.70 to 1.38) 15.66 0.53 81 2.77 (−0.97 to 6.51) 16.93 0.53
BSA < 1.60 34 3.18 (−1.76 to −8.14) 14.20 0.46 32 2.24 (−2.83 to 7.33) 14.10 0.62 2 18.25 (−3.65 to 40.16) 2.43 <0.05
BSA 1.60-1.79 70 1.08 (−3.69 to 5.86) 20.02 0.76 52 −3.13 (−7.88 to 1.62) 17.08 0.35 18 13.26 (1.69 to 24.83) 23.27 0.17
BSA > 1.80 81 −1.63 (−4.58 to 1.30) 13.29 0.69 20 −4.09 (−10.45 to 2.25) 13.57 0.52 61 −0.83 (−4.21 to 2.55) 13.22 0.86

















Figure 1 Bland altman plot 51cr-EDTA versus CKD-EPI formula.
51cr-EDTA: 51 chromium ethylene diamine tretraacetic acid clearance;
CKD-EPI: Chronic kidney disease epidemiology collaboration.
Figure 2 Bland altman plot 51cr-EDTA versus MDRD formula.
51cr-EDTA: 51 chromium ethylene diamine tretraacetic acid clearance;
MDRD: Modification of diet in renal disease.
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As shown in Table 1, the mean patient age exceeded
60 years, with a range of 26 to 83 years. There were
more females than males. The mean absolute m-GFR
was 88 ± 25 ml/min, (Range 33–156 ml/min) which
means that there were no patients with CKD IV and V
included in this study.
32 (17%) patients had m-GFR > 110 ml/min, with a
median of 120 ml/min (111–156).
There were 23 (12%) patients with a GFR less than 60
ml/min (Range 33–59), median 49 ml/min.
The average BSA in this study was 1.78 ± 0.20 m2,
higher than the standard BSA of 1.73 m2, with a range
of 1.23 to 2.30 m2. In comparison BMI mean was 24.2
kg/m2 and range 15.6 to 36.4 kg/m2.
Bias, precision and accuracy results of e-GFR with CKD-EPI
and MDRD formulae
With regards to CKD-EPI, Table 2 shows that bias was
lower than in the previous study based on BSA indexed
data (0.49 vs. 1.16), precision was also slightly better
(12.95 versus 13.37) but the best results arose from the
higher P30 which crossed the level of 90%, considered as
the reference value for a good accuracy (92.43% versus
89.73%) [18].
The bias for the whole group was even lower for
MDRD, but the P30 was not above 90% and precision
was lower than for CKD-EPI.
When looking at the same analysis stratified by different
levels of BSA, we found that in the group of patients
with BSA more than 1.80 m2 with CKD-EPI formula,
there is an improvement in the results as compared to
MDRD, with a bias of −0.68 ml/min, a high precision
(11.85 vs. 12.95) and a higher P10 (56.79 vs. 52.43%) as
well as P30 (98.77 vs. 92.43%).
Comparison of measured absolute values versus
estimated absolute values
Table 3 shows the bias between absolute values obtained
with the gold standard method and both estimation
formulae. In other words, the normalization factor was
removed.
This analysis showed that there were no differences in
between GFR values obtained with 51Cr-EDTA and
CKD-EPI or MDRD estimation formulae, as long as the
absolute values are used.
An analysis of data stratified by BSA showed that there
was a clinical significant difference in the group of males
with BSA < 1.60 m2 for both formula, but there were
only 2 participants in the group. This difference was
disregarded.
By looking at the data in a graphic manner with
Bland-Altman plot it is quite clear to see that the com-
parison between 51Cr-EDTA and CKD-EPI (Figure 1),demonstrates that most values are around 0 with a lesser
spreading of data and no outliners. Data for MDRD is
more spread, showing that this method is less compar-
able to 51Cr-EDTA (Figure 2).
Comparison of BSA indexed and absolute GFR values for
all three methods
When differences in between indexed and absolute
values for all three methods were analyzed, as shown in
Table 4, a very similar bias was found across all three
methods, suggesting that the bias is related to the BSA
normalization factor.
There was a significant bias in all three groups as a
whole as well as whenever BSA was > 1.80 m2.
These results showed that in patients with the lowest
BSA under 1.60 m2 there was a significant overestimation
of GFR patent with all three methods, demonstrating that
the tendency can be found with the gold standard method
as well as the estimation formula.
There were no clinical or statistical differences between
mean bias for patients with at BSA <1.60 m2 measured
with 51Cr-EDTA (10.23 ± 4.76 ml/min) and mean bias
for the same group calculated with CKD-EPI (11.08 ±
5.82 ml/min) as p value was 0.51.
Table 4 Differences in between BSA indexed GFR (ml/min per 1.73 m2) and absolute GFR values (ml/min) for 51Cr-EDTA, CKD-EPI and MDRD
All Women Men
n Mean bias (95% C.I) Std dev. P value n Mean bias (95% C.I) Std dev. P value n Mean bias (95% C.I) Std dev. P value
51cr-EDTA
all 185 −3.01 (−4.57 to −1.46) 11 <0.001 104 2.42 (0.90 to 3.94) 7.81 <0.01 81 −10.09 (−12.18 to −7.83) 9.82 <0.001
BSA < 1.60 34 10.23 (8.57 to 11.90) 4.76 <0.001 32 10.48 (8.74 to 12.21) 4.80 <0.001 2 6.37 (−0.06 to 12.76) 0.71 0.0505
BSA 1.60-1.79 70 1.55 (0.84 to 2.25) 2.95 <0.001 52 1.84 (1.05 to 2.63) 2.83 <0.001 18 0.70 (−0.89 to 2.29) 3.2 0.37
BSA > 1.80 81 −12.53 (−14.26 to −10.79) 7.84 <0.001 20 −8.95 (−11.28 to −6.63) 4.97 <0.001 61 −13.70 (−15.82 to −11.58) 8.28 <0.001
CKD-EPI
all 185 −2.75 ( −4.31 to −1.19) 10.75 <0.001 104 2.67 (1.07 to 4.27) 8.22 <0.01 81 −9.73 (−11.84 to −7.61) 9.57 <0.001
BSA < 1.60 34 11.08 (9–05 to 13.11) 5.82 <0.001 32 11.24 (9.09 to 13.39) 5.96 <0.001 2 8.51 (−1.30 to 18.33) 1.09 0.057
BSA 1.60-1.79 70 1.57 (0.86 to 2.28) 2.97 <0.001 52 1.87 (1.09 to 2.64) 2.78 <0.001 18 0.71 (−0.98 to 2.40) 3.4 0.38
BSA > 1.80 81 −12.31 ( −13.94 to −10.68 7.37 <0.001 20 −8.94 (−11.02 to −6.86) 4.44 <0.001 61 −13.41 ( −15.41 to −11.41) 7.82 <0.001
MDRD
all 185 −2.68 ( −4.26 to −1.11) 10.85 <0.001 104 2.80 (1.21 to 4.38) 8.15 <0.001 81 - 9.72 (−11.89 to −7.55) 9.5 <0.001
BSA < 1.60 34 11.10 (8.87 to 13.32) 6.38 <0.001 32 11.27 (8.91 to 13.63) 6.54 <0.001 2 8.53 (−1.60 to 18.30) 1.1 0.059
BSA 1.60-1.79 70 1.63 (0.87 to 2.39) 3.20 <0.001 52 1.85 (1.07 to 2.63) 2.80 <0.001 18 0.98 (−1.08 to 3.06) 4.16 0.32
BSA > 1.80 81 −12.20 ( −13.86 to −10.54) 7.52 <0.001 20 −8.30 (−10.19 to −6.41) 4.04 <0.001 61 −11.44 (−15.52 to −12.50) 7.97 <0.001

















Redal-Baigorri et al. BMC Nephrology 2013, 14:271 Page 7 of 8
http://www.biomedcentral.com/1471-2369/14/271The same results applied to the comparison be-
tween 51Cr-EDTA and MDRD where p value was 0.53.
The opposite effect was observed in the group of
patients with BSA over 1.80 m2, as there was an under-
estimation of the measured GFR with all three methods
if the BSA indexed GFR value was used.
Again there were no differences in the mean bias
between all three methods, as underestimation of GFR
by 51Cr-EDTA of −12.53 ± 7.84 ml/min compared to
underestimation by CKD-EPI of −12.31 ± 7.37 ml/min
(n = 81) showed a p value of 0.85. Same analysis with
MDRD values showed a p value of 0.78.
Table 5 shows the analysis of bias between 51Cr-EDTA
and the two estimation methods stratified by age. The
chosen range is 25 to >70 years, as the youngest patient
was 25.64 and the oldest was 83.42 years old. As demon-
strated in Table 3 by BSA stratification, no differences
are found in the 3 chosen groups. The best results can
be observed with CKD-EPI formula in the group of
patients with an age range between 51 and 70 years, as
bias is as low as 0.07 and no significant clinical or stat-
istical differences between the reference method and
the estimation formula are found.Discussion
To our knowledge this is the first clinical study of a group
of patients in a creatinine steady state, comparing the
performance of MDRD and CKD-EPI GFR estimation
equation expressed in absolute values and not BSA indexed
values, with a reference method for measuring GFR.
The absolute GFR values obtained with both estima-
tion formulae are very similar to the results obtained
with 51Cr-EDTA, suggesting that the performance of
both formulae can be improved if the BSA normalization
factor is removed, but in general CKD-EPI performance
was slightly better measured with different parameters.Table 5 Comparison of CKD-EPI and MDRD versus 51Cr-EDTA
n BSA
CDK-EPI VERSUS 51-CR-EDTA ml/min
All 185 1.78 ± 0.20
25-50 years 22 1.88 ± 0.20
51-70 years 120 1.77 ± 0.20
> 70 years 43 1.75 ± 0.20
MDRD VERSUS 51CR-EDTA ml/min
All 185 1.78 ± 0.20
25-50 years 22 1.88 ± 0.20
51-70 years 120 1.77 ± 0.20
> 70 years 43 1.75 ± 0.20
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration formula; MDRD: ModifThis study also shows what other studies have sug-
gested, with increasing BSA there is an underestimation
of GFR as long as the BSA indexed values are used,
what is new in this study is that this underestimation is
eliminated if the absolute values are used, improving
the performance of CKD-EPI and MDRD formulae in
all groups regardless BSA.
The best results regarding bias, precision and accuracy
were obtained for CKD-EPI formula in the group of
patients with BSA >1.80, showing a P30 of 98.77%, and
an underestimation of only 0.68 ml/min with regards
to 51Cr-EDTA.
By looking at the different age groups, the best results
were also found with the CKD-EPI formula in the range
of 51 to 70 years with a bias as low as 0.07 ml/min.
The Bland Altman plots show that the best results are
seen with CKD-EPI, with a good concentration of values
around the bias line.
A review about BSA indexing renal function parame-
ters by Delanaye et al. [19] has argued against using BSA
indexed measured GFR values, especially if the results
are to be used for drug dosing in an obese population or
GFR longitudinal follow-up purposes, but they do not
recommend to “de-index” MDRD in patients with a BSA
over 2.4 m2, because the MDRD formula was based on
patients with a BSA range between 1.5 and 2.4 m2.
In this study we demonstrate that de-indexation of
estimated GFR by MDRD or CKD-EPI follows the same
trend as absolute measured GFR by 51Cr-EDTA, but our
population has a BSA range of 1.23 to 2.30 m2.
By expressing the raw estimated GFR values, factors
such as cachexia or obesity are removed, and that might
avoid under and overestimation largely observed in
many studies, which could contribute to a more accurate
dose calculation of GFR based drugs, such as carboplatin
and a reduction of the inaccuracies in drug dosing
reported by other studies [5,20].as absolute GFR values (ml/min) stratified by age
All participants
Mean bias (95% C.I) Std dev. P value
0.49 (−1.38 to 2.37) 12.95 0.83
−1.18 (−7.22 to 4.86) 13.63 0.87
0.07 (−2.45 to 2.59) 13.97 0.98
2.55 (−0.25 to 5.34) 9.10 0.50
0.27 (−2.09 to 2.64) 16.33 0.91
3.18 (−1.76 to −8.14) 14.20 0.46
1.08 (−3.69 to 5.86) 20.02 0.76
−1.63 (−4.58 to 1.30) 13.29 0.69
ication of diet in renal disease formula; BSA: Body surface area.
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to BSA based GFR estimation formula, suggesting other
parameters such as lean body mass [3] but if the goal of
estimating GFR is drug dosing or an individual assessment
of kidney function, the absolute values without further
correction might be more accurate and easy to calculate.
In those cases where GFR is used to compare popu-
lations, the use of extracellular volume (ECV) as
normalization factor seems to be more adequate as
BSA, body mass index (BMI) and lean body mass are
all related to weight and height, but measuring ECV
is not feasible in daily practice [4].
Conclusions
In view of these facts we recommend clinicians to convert
the estimated GFR values obtained with CKD-EPI to
the absolute GFR values whenever the individual kidney
function needs to be investigated, as bias with regards
to the reference method is rather low. These considerations
might also apply to other groups of patients when cal-
culating dose of nephrotoxic drugs, as recommended
by NKDEP or in assessing GFR for other purposes such
as suitability for living kidney donation [13] or indication
for renal replacement therapy.
Relevant organizations might consider expressing GFR
estimation equations as absolute values as well as BSA
indexed values, leaving clinicians the opportunity to use
the most relevant value for a given patient in different
clinical situations [21].
A prospective study looking at the impact in chemo-
therapy drug dosing intention by using GFR estimation
formula expressed in absolute values is desirable, as such
an study might show whether there are clinical conse-
quences or not.
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